Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).

Garziera M, Cecchin E, Canzonieri V, Sorio R, Giorda G, Scalone S, De Mattia E, Roncato R, Gagno S, Poletto E, Romanato L, Sartor F, Polesel J, Toffoli G.

Int J Mol Sci. 2018 May 18;19(5). pii: E1510. doi: 10.3390/ijms19051510.

PMID:
29783665
2.

Passive Versus Active Circuit During Invasive Mechanical Ventilation in Subjects With Amyotrophic Lateral Sclerosis.

De Mattia E, Falcier E, Lizio A, Lunetta C, Sansone VA, Barbarito N, Garabelli B, Iatomasi M, Roma E, Rao F, Carlucci A.

Respir Care. 2018 May 15. pii: respcare.05866. doi: 10.4187/respcare.05866. [Epub ahead of print]

PMID:
29765003
3.

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, Toffoli G.

Front Pharmacol. 2018 Apr 13;9:367. doi: 10.3389/fphar.2018.00367. eCollection 2018.

4.

Impact of an early respiratory care programme with non-invasive ventilation adaptation in patients with amyotrophic lateral sclerosis.

Vitacca M, Montini A, Lunetta C, Banfi P, Bertella E, De Mattia E, Lizio A, Volpato E, Lax A, Morini R, Paneroni M; ALS RESPILOM Study Group.

Eur J Neurol. 2018 Mar;25(3):556-e33. doi: 10.1111/ene.13547. Epub 2018 Jan 29.

PMID:
29266547
5.

Genetic biomarkers for hepatocellular cancer risk in a caucasian population.

De Mattia E, Cecchin E, Polesel J, Bignucolo A, Roncato R, Lupo F, Crovatto M, Buonadonna A, Tiribelli C, Toffoli G.

World J Gastroenterol. 2017 Sep 28;23(36):6674-6684. doi: 10.3748/wjg.v23.i36.6674.

6.

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.

Labriet A, De Mattia E, Cecchin E, Lévesque É, Jonker D, Couture F, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G, Guillemette C.

Front Pharmacol. 2017 Oct 10;8:712. doi: 10.3389/fphar.2017.00712. eCollection 2017.

7.

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G.

Int J Mol Sci. 2017 Jul 14;18(7). pii: E1522. doi: 10.3390/ijms18071522. Review.

8.

HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.

Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, Polesel J, D'Andrea M, Pella N, Buonadonna A, Favaretto A, Toffoli G.

Int J Mol Sci. 2017 Jun 27;18(7). pii: E1366. doi: 10.3390/ijms18071366.

9.

Use of the Intermittent Abdominal Pressure Ventilation to guarantee speech in a tracheostomized Amyotrophic Lateral Sclerosis patient.

De Mattia E, Iatomasi M, Garabelli B, Lunetta C, Sansone VA, Rao F.

Rev Port Pneumol (2006). 2017 Jul - Aug;23(4):236-239. doi: 10.1016/j.rppnen.2017.03.002. Epub 2017 May 31. No abstract available.

10.

UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population.

De Mattia E, Cecchin E, Polesel J, Lupo F, Tiribelli C, Crovatto M, Buonadonna A, Toffoli G.

Liver Int. 2017 Sep;37(9):1345-1353. doi: 10.1111/liv.13411. Epub 2017 Apr 6.

PMID:
28294511
11.

Obesity paradox in chronic obstructive pulmonary disease: A result of airflow obstruction over-grading?

Barbarito N, De Mattia E.

Respir Med. 2017 May;126:133. doi: 10.1016/j.rmed.2016.08.012. Epub 2016 Oct 18. No abstract available.

PMID:
28277281
12.

Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.

Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, Buonadonna A, Solfrini V, Innocenti F, Toffoli G.

Clin Pharmacol Ther. 2017 Jan 11. doi: 10.1002/cpt.615. [Epub ahead of print]

PMID:
28074472
13.

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.

Cesaratto L, Grisard E, Coan M, Zandonà L, De Mattia E, Poletto E, Cecchin E, Puglisi F, Canzonieri V, Mucignat MT, Zucchetto A, Stocco G, Colombatti A, Nicoloso MS, Spizzo R.

Cell Death Dis. 2016 Dec 22;7(12):e2526. doi: 10.1038/cddis.2016.448. No abstract available.

14.

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.

Cesaratto L, Grisard E, Coan M, Zandonà L, De Mattia E, Poletto E, Cecchin E, Puglisi F, Canzonieri V, Mucignat MT, Zucchetto A, Stocco G, Colombatti A, Nicoloso MS, Spizzo R.

Cell Death Dis. 2016 Sep 22;7(9):e2374. doi: 10.1038/cddis.2016.278. Erratum in: Cell Death Dis. 2016 Dec 22;7(12 ):e2526.

15.

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.

Dreussi E, Cecchin E, Polesel J, Canzonieri V, Agostini M, Boso C, Belluco C, Buonadonna A, Lonardi S, Bergamo F, Gagno S, De Mattia E, Pucciarelli S, De Paoli A, Toffoli G.

Int J Mol Sci. 2016 Sep 5;17(9). pii: E1482. doi: 10.3390/ijms17091482.

16.

Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.

De Mattia E, Cecchin E, Roncato R, Toffoli G.

Pharmacogenomics. 2016 Sep;17(14):1547-71. doi: 10.2217/pgs-2016-0095. Epub 2016 Aug 26. Review.

PMID:
27561454
17.

Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.

Dreussi E, Pucciarelli S, De Paoli A, Polesel J, Canzonieri V, Agostini M, Friso ML, Belluco C, Buonadonna A, Lonardi S, Zanusso C, De Mattia E, Toffoli G, Cecchin E.

Oncotarget. 2016 Apr 12;7(15):19781-93. doi: 10.18632/oncotarget.7757.

18.

Nuclear receptors and drug metabolism for the personalization of cancer therapy.

Cecchin E, De Mattia E, Toffoli G.

Expert Opin Drug Metab Toxicol. 2016;12(3):291-306. doi: 10.1517/17425255.2016.1141196. Epub 2016 Feb 1. Review.

PMID:
26789519
19.

HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

Garziera M, Bidoli E, Cecchin E, Mini E, Nobili S, Lonardi S, Buonadonna A, Errante D, Pella N, D'Andrea M, De Marchi F, De Paoli A, Zanusso C, De Mattia E, Tassi R, Toffoli G.

PLoS One. 2015 Dec 3;10(12):e0144000. doi: 10.1371/journal.pone.0144000. eCollection 2015.

20.

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

De Mattia E, Cecchin E, Toffoli G.

Drug Resist Updat. 2015 May;20:39-70. doi: 10.1016/j.drup.2015.05.003. Epub 2015 May 22. Review.

PMID:
26027741
21.

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.

Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G.

Pharmacogenomics J. 2015 Jun;15(3):219-25. doi: 10.1038/tpj.2014.64. Epub 2014 Oct 21.

PMID:
25331073
22.

A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.

Cecchin E, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G.

Int J Biol Markers. 2014 Dec 9;29(4):e310-6. doi: 10.5301/jbm.5000095.

PMID:
24855036
23.

Grading the severity of obstruction in patients with chronic obstructive pulmonary disease and morbid obesity.

Barbarito N, De Mattia E.

Monaldi Arch Chest Dis. 2013 Sep-Dec;79(3-4):121-7.

24.

Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?

De Mattia E, Dreussi E, Cecchin E, Toffoli G.

Pharmacogenomics. 2013 Dec;14(16):2035-54. doi: 10.2217/pgs.13.214. Review.

PMID:
24279858
25.

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.

De Mattia E, Toffoli G, Polesel J, D'Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, Cecchin E.

Pharmacogenet Genomics. 2013 Oct;23(10):549-57. doi: 10.1097/FPC.0b013e328364b6cf.

PMID:
24018773
26.

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.

Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G.

Pharmacogenomics J. 2013 Oct;13(5):403-9. doi: 10.1038/tpj.2012.31. Epub 2012 Aug 7.

27.
28.

Which mask for noninvasive ventilation in acute respiratory failure?

Barbarito N, Vaghi A, De Mattia E.

Chest. 2011 Oct;140(4):1103. doi: 10.1378/chest.11-1223. No abstract available.

PMID:
21972397
29.

Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.

Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, De Mattia E, Friso ML, Biason P, Visentin M, Nitti D, Toffoli G.

Pharmacogenomics J. 2011 Jun;11(3):214-26. doi: 10.1038/tpj.2010.25. Epub 2010 Apr 6.

PMID:
20368715
30.

MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer.

De Re V, Cannizzaro R, Canzonieri V, Cecchin E, Caggiari L, De Mattia E, Pratesi C, De Paoli P, Toffoli G.

Tumour Biol. 2010 Jan;31(1):23-32. doi: 10.1007/s13277-009-0004-1. Epub 2009 Dec 18.

31.

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F.

J Clin Oncol. 2010 Feb 10;28(5):866-71. doi: 10.1200/JCO.2009.23.6125. Epub 2009 Dec 28.

32.

Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.

Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M.

Clin Cancer Res. 2009 May 15;15(10):3550-6. doi: 10.1158/1078-0432.CCR-08-2249.

33.

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G.

J Clin Oncol. 2009 May 20;27(15):2457-65. doi: 10.1200/JCO.2008.19.0314. Epub 2009 Apr 13.

PMID:
19364970
34.

C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.

De Mattia E, Toffoli G.

Eur J Cancer. 2009 May;45(8):1333-51. doi: 10.1016/j.ejca.2008.12.004. Epub 2009 Jan 12. Review.

PMID:
19144510
35.

Pharmacogenetic relevance of MTHFR polymorphisms.

Toffoli G, De Mattia E.

Pharmacogenomics. 2008 Sep;9(9):1195-206. doi: 10.2217/14622416.9.9.1195. Review.

PMID:
18781847
36.

Pharmacology of epidermal growth factor inhibitors.

Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S24-39. Review.

PMID:
17520578
37.

Pharmacology of epidermal growth factor inhibitors.

Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G.

Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):24-39. doi: 10.5301/JBM.2008.5634.

PMID:
28207111
38.

Physiological response to intrapulmonary percussive ventilation in stable COPD patients.

Nava S, Barbarito N, Piaggi G, De Mattia E, Cirio S.

Respir Med. 2006 Sep;100(9):1526-33. Epub 2006 Feb 21.

39.

Muscle retraining in ICU patients.

Cirio S, Piaggi GC, De Mattia E, Nava S.

Monaldi Arch Chest Dis. 2003 Oct-Dec;59(4):300-3. Review.

PMID:
15148840
40.

Weaning from tracheotomy in long-term mechanically ventilated patients: feasibility of a decisional flowchart and clinical outcome.

Ceriana P, Carlucci A, Navalesi P, Rampulla C, Delmastro M, Piaggi G, De Mattia E, Nava S.

Intensive Care Med. 2003 May;29(5):845-8. Epub 2003 Mar 13.

PMID:
12634987
41.

Muscle retraining in the ICU patients.

Nava S, Piaggi G, De Mattia E, Carlucci A.

Minerva Anestesiol. 2002 May;68(5):341-5. Review.

42.

[Immunotherapy].

DE MATTIA E.

Imprensa Medica. 1949 Mar;24(423):76-8. Portuguese. No abstract available.

PMID:
18120895

Supplemental Content

Loading ...
Support Center